(380) The Effect of Contemporary Oncologic Agents on Fertility Outcomes: A Review of the Literature.

This article reviews the effects of contemporary oncologic agents—defined as those approved by the U.S. Food and Drug Administration since 2006—on fertility outcomes, focusing on chemotherapy, immunotherapy, and targeted therapies commonly encountered by urologists. An institutional review identified 28 such agents used in 75 patients, with a literature search yielding 56 relevant studies assessing impacts on spermatogenesis, ovarian function, and related reproductive parameters. Findings indicate significant variability in fertility effects, with alkylating agents and immune checkpoint inhibitors, such as melphalan and ipilimumab, most frequently associated with impaired fertility. The study highlights limited and sometimes conflicting evidence on fertility outcomes, underscoring the need for increased provider awareness and further research in oncofertility.